Clinical Trials | April 08, 2026
Amgen’s TEPEZZA injection clears Phase 3 trial with high efficacy
The trial also demonstrated significant improvements across multiple secondary endpoints
The trial also demonstrated significant improvements across multiple secondary endpoints
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
The company spotlights micronutrient’s role in immunity, skin and bone health through digital and radio outreach on National Vitamin C Day
Its a major breakthrough for women’s ovarian cancer care in Europe
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
This marks a meaningful step in the company's continued expansion in the region
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
